Treatment of platinum refractory or resistant ovarian cancer.

Gabriella Ferrandina, Giacomo Corrado

Journal: The Lancet. Oncology 2019;19(9):1147-1149

PMID: 30100380

Full Text on Elsevier Science View on PubMed

Abstract

Address: Department of Woman and Child Health, Gynecologic Oncology Unit, Fondazione "Policlinico Universitario A. Gemelli", IRCSS, Universita' Cattolica Sacro Cuore, Rome, Italy. Electronic address: [email protected].; Department of Woman and Child Health, Gynecologic Oncology Unit, Fondazione "Policlinico Universitario A. Gemelli", IRCSS, Universita' Cattolica Sacro Cuore, Rome, Italy.

DOI: 10.1016/S1470-2045(18)30428-5

Link outs

Free resources

Medical:

https://medlineplus.gov/ovariancancer.html

Other Literature Sources:

https://scite.ai/reports/30100380

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S1470...
https://www.clinicalkey.com/content/playBy/pii?v=S...

MeSH Terms: Double-Blind Method, Female, Humans, Neoplasm Recurrence, Local, Ovarian Neoplasms, Platinum, Sorafenib, Topotecan